Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive Cancers
Alectinib has demonstrated activity in children with ALK fusion-positive cancers in a phase 1/2 trial.
Alectinib has demonstrated activity in children with ALK fusion-positive cancers in a phase 1/2 trial.
Leland Metheny, MD, discusses ongoing clinical trials and their implications for the field of hematologic oncology.
Agencje rejestrujące leki, takie jak FDA czy EMA, mogą dopuszczać leki w procedurze przyspieszonej lub warunkowo. Bywa, że jeśli lek okaże się nieskuteczny, może zostać…
Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer.
Childhood cancer survivors are at high risk of long-term iatrogenic events, in particular those treated with radiotherapy. The prediction of risk of such events is…
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
Defects in RNA processing can promote cancer — but the mutated proteins responsible can be hard to target. Fred Hutch Cancer Center and Memorial Sloan…
Researchers uncover lung adenocarcinoma’s early roots, tracing the cancer back to a specific cell type. These insights offer new hope for detection and prevention.
Nature Reviews Cancer – In this Journal Club, Oh and Kim discuss a study demonstrating the mechanisms underlying histological transformation of lung adenocarcinoma to neuroendocrine…
Nature Reviews Cancer – Connie J. Eaves (1944–2024)
Nature Reviews Cancer – In this Review, Zhang and colleagues provide an overview of the molecular characteristics of paediatric cancer and highlight how these malignancies…